Q-omics provides the consensus-scored JAG1 profile across patient tissues and cancer cell-line models. JAG1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, JAG1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, JAG1 RNA expression shows 19,884 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, HNSC, and KIRP as cancer lineages where JAG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JAG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JAG1 survival associations across molecular data types. JAG1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JAG1 RNA expression–survival associations across cancer types. High JAG1 expression shows unfavorable associations in ACC, UVM, PAAD and LGG, but favorable associations in KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for JAG1 RNA expression.
This table summarizes JAG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for JAG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JAG1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, STAD and LUSC. The HNSC box plot shows higher JAG1 RNA expression in tumor versus normal tissue (log2 FC = +1.864, t-test p < 0.001).
This table shows molecular features associated with JAG1 in patient tissues and cancer cell lines. In patient samples, JAG1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, JAG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
